影响接受曲妥珠单抗联合化疗的晚期HER2阳性胃癌临床结局的分子特征

数据集获取（Figshare）

• 源站标题：Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy
• DOI：10.6084/m9.figshare.30552965.v1
• 发布日期：2025-11-06
• 文件数：4 个
• 文件总体积：7.25 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Molecular_features_influencing_clinical_outcome_of_advanced_HER2-positive_gastric_cancer_receiving_trastuzumab_plus_chemotherapy/30552965

命令行下载

curl -L -o "iann_a_2581815_sm6669.docx" "https://ndownloader.figshare.com/files/59351048"
curl -L -o "iann_a_2581815_sm7491.tif" "https://ndownloader.figshare.com/files/59351051"
curl -L -o "iann_a_2581815_sm7490.tif" "https://ndownloader.figshare.com/files/59351054"
curl -L -o "iann_a_2581815_sm7489.tif" "https://ndownloader.figshare.com/files/59351057"

文件清单

• iann_a_2581815_sm6669.docx（31.39 KB）
• iann_a_2581815_sm7491.tif（2.20 MB）
• iann_a_2581815_sm7490.tif（941.12 KB）
• iann_a_2581815_sm7489.tif（4.08 MB）

文件总体积 7.25 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Less than half of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) patients respond to trastuzumab plus chemotherapy, and the outcomes are unsatisfactory. Understanding the underlying mechanisms remains crucial for identifying patients who are more likely to benefit from treatment.
We performed targeted DNA sequencing on paired pre-treatment and progressive tumour tissues from 22 HER2-positive advanced GC patients undergoing first-line treatment with trastuzumab and chemotherapy. Clinicopathological and genomic characteristics were assessed for the correlation with clinical outcomes.
A performance status (PS) of 0–1 was associated with improved progression-free survival (PFS) and overall survival (OS) than a PS of 2. Poorly differentiated tumours exhibited shorter PFS than moderate or moderate-poor ones. Pre-treatment amplification of MYC or TOP2A gene was association with increased PFS, and suggested a potential benefit for OS. Patients with higher tumour mutation burden (TMB) experienced significantly worse PFS, while higher chromosome instability (CIN) appeared to be correlated with longer PFS. Compared to non-responders, responders had a higher CIN but similar TMB and intratumoural heterogeneity (ITH). PS and MYC amplification emerged as independent factors related to PFS according to multivariate survival analysis. Additionally, after treatment, TMB significantly increased in non-responders, while CIN significantly decreased in responders.
Pre-treatment MYC amplification and PS were independently associated with clinical outcomes in HER2-positive advanced GC patients treated with first-line trastuzumab plus chemotherapy. Dynamic post-treatment changes in TMB and CIS provide valuable insights into the relationship between therapeutic response and distinct evolutionary trajectories.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.30552965.v1（source: https://tandf.figshare.com/articles/dataset/Molecular_features_influencing_clinical_outcome_of_advanced_HER2-positive_gastric_cancer_receiving_trastuzumab_plus_chemotherapy/30552965）。